TAK: Takeda Pharmaceutical Co., Ltd.
About
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Current Value
$13.481 Year Return
Current Value
$13.481 Year Return
Key Details
Market Cap
$43.18B
P/E Ratio
22.29
1Y Stock Return
-2.85%
1Y Revenue Growth
1.12%
Dividend Yield
4.04%
Price to Book
0.9
Strategies that include TAK
Stock's related to TAK
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ALGN | 39.91% | $16.62B | +3.38% | 0.00% |
| MUFG | 37.80% | $138.35B | +39.37% | 1.09% |
| SMFG | 37.75% | $92.69B | +43.10% | 1.20% |
| WCN | 35.91% | $48.39B | +42.47% | 0.62% |
| MO | 35.46% | $94.67B | +37.05% | 7.07% |
| HMC | 35.27% | $41.71B | -13.16% | 5.36% |
| TLK | 34.12% | $16.88B | -27.18% | 6.58% |
| WHR | 33.19% | $6.05B | +0.98% | 6.44% |
| MFG | 32.14% | $63.12B | +43.52% | 1.44% |
| PFGC | 31.89% | $12.91B | +33.83% | 0.00% |
| RCI | 31.83% | $19.13B | -16.28% | 4.11% |
| IGT | 31.81% | $3.83B | -28.66% | 4.24% |
| XPRO | 31.33% | $1.51B | -16.97% | 0.00% |
| CCEP | 30.70% | $35.03B | +25.13% | 2.78% |
| VMI | 30.53% | $6.80B | +61.98% | 0.71% |
| EIG | 30.51% | $1.30B | +38.83% | 2.25% |
| WEX | 30.47% | $7.10B | +2.88% | 0.00% |
| WU | 30.02% | $3.63B | -9.74% | 8.78% |
| SKM | 29.94% | $8.53B | -0.67% | 6.32% |
| RPRX | 29.94% | $11.56B | -3.67% | 3.22% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IBM | -<0.01% | $194.41B | +36.61% | 3.16% |
| GPCR | -0.01% | $1.88B | -36.14% | 0.00% |
| HSII | 0.03% | $914.74M | +64.66% | 1.35% |
| KMB | -0.03% | $45.22B | +11.57% | 3.58% |
| TME | 0.05% | $7.80B | +28.31% | 1.22% |
| LFCR | 0.05% | $261.10M | -4.58% | 0.00% |
| MPW | -0.07% | $2.60B | -4.63% | 12.59% |
| CFLT | -0.08% | $9.28B | +49.05% | 0.00% |
| PPC | -0.15% | $12.38B | +100.96% | 0.00% |
| BTSG | 0.17% | $3.25B | +43.46% | 0.00% |
| ASR | 0.20% | $7.56B | +26.22% | 0.00% |
| CMG | 0.23% | $80.02B | +33.62% | 0.00% |
| PULM | 0.25% | $19.83M | +202.98% | 0.00% |
| APEI | 0.28% | $339.36M | +232.64% | 0.00% |
| IDT | 0.29% | $1.26B | +74.67% | 0.30% |
| JCI | 0.35% | $55.80B | +59.01% | 1.77% |
| QTTB | 0.58% | $354.34M | +188.64% | 0.00% |
| ALKS | 0.58% | $4.45B | +15.66% | 0.00% |
| BYRN | 0.58% | $479.70M | +295.19% | 0.00% |
| TKO | -0.59% | $10.62B | +67.14% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FCN | -18.27% | $7.10B | -10.74% | 0.00% |
| ITGR | -13.73% | $4.48B | +49.37% | 0.00% |
| JBI | -11.90% | $1.00B | -31.76% | 0.00% |
| HUSA | -11.57% | $16.69M | -11.56% | 0.00% |
| CAPR | -11.51% | $839.37M | +532.19% | 0.00% |
| EVER | -11.34% | $664.25M | +124.76% | 0.00% |
| ABNB | -10.79% | $82.12B | +3.64% | 0.00% |
| PI | -10.71% | $5.17B | +122.46% | 0.00% |
| CANG | -10.66% | $253.50M | +212.50% | 0.00% |
| OXBR | -10.56% | $19.05M | +178.18% | 0.00% |
| NTZ | -10.41% | $47.64M | -30.94% | 0.00% |
| UTI | -10.39% | $1.07B | +73.54% | 0.00% |
| EME | -10.29% | $23.65B | +140.34% | 0.18% |
| CMTL | -9.90% | $84.44M | -76.16% | 0.00% |
| VHC | -9.29% | $19.06M | -38.36% | 0.00% |
| BPMC | -9.29% | $6.01B | +42.68% | 0.00% |
| AGX | -9.06% | $2.01B | +224.91% | 0.85% |
| WSR | -8.80% | $738.93M | +33.24% | 3.37% |
| MPC | -8.68% | $51.04B | +7.57% | 1.57% |
| FUN | -8.66% | $4.60B | -16.51% | 0.00% |
ETF's related to TAK
News
Yahoo
The companies have teamed up to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platforms.
Yahoo
Gabriele Ricci, chief data and technology officer, has been reorganizing the technology function at Takeda Pharmaceutical.
Yahoo
Takeda Canada Inc. ("Takeda") announces new data highlighting the impact Inflammatory Bowel Disease (IBD) has on Canadians. The data reveals insights into how the disease affects daily life, the challenges to timely access to care and treatment, and the unmet need to prioritize mental health support for those living with IBD.
SeekingAlpha
The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2025 Q2 earnings call.
SeekingAlpha
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2025 Earnings Call October 31, 2024 6:00 AM ETCompany ParticipantsChristopher OâReilly - Head, Investor...
Yahoo
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$20 million milestone payment from its partner Takeda (TSE:4502/NYSE:TAK), triggered by reaching over US$200 million in sales of FRUZAQLA® (fruquintinib) for metastatic colorectal cancer (“CRC”). CRC is the second most commo
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.